In a retrospective study, median survival was greater in patients who received a B-RAF TKI after, rather than during or before, SRS for brain metastases but the incidence of intracranial haemorrhage was higher (10.4%) in the B-RAF TKI group as compared with 3% in the those who did not receive the targeted therapy [69]. This evidence concerns the gene BRAF and hemorrhage.